fig6
From: Adjuvant role of a T-type calcium channel blocker, TTA-A2, in lung cancer treatment with paclitaxel
Figure 6. Compared to the negative control, treatment with TTA-A2 significantly reduced Cav3.1 and Cav3.2 mRNA expression in all treatment groups. Furthermore, Pgp expression varied non-significantly among the groups (non-significant P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001). Pgp: P-glycoprotein.
